Coxibs, non-steroidal anti-inflammatory drugs and cardiovascular risk

Internal Medicine Journal

Volumn 36, Issue 5, 2006, Pages 308-319

  Hermann, M ^a   Ruschitzka, F ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Coxib; Cyclooxygenase; Inflammation; Nitric oxide; NSAID

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; ETORICOXIB; IBUPROFEN; INDOMETACIN; LUMIRACOXIB; MELOXICAM; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PARECOXIB; PLACEBO; ROFECOXIB; SULINDAC; THROMBOPLASTIN; VALDECOXIB;

ACUTE HEART INFARCTION; ARTERY INTIMA PROLIFERATION; BLEEDING; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELL PROLIFERATION; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; ENDOTHELIUM; ENZYME INHIBITION; GASTROINTESTINAL SYMPTOM; HEART FAILURE; HEART INFARCTION; HEART PROTECTION; HUMAN; HYPERTENSION; KIDNEY DISEASE; OXIDATIVE STRESS; PAIN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SMOOTH MUSCLE FIBER; STROKE; THROMBOSIS; TREATMENT DURATION; VASCULAR SMOOTH MUSCLE;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BLOOD VESSELS; CARDIOVASCULAR DISEASES; CHRONIC DISEASE; CYCLOOXYGENASE 2 INHIBITORS; HEART FAILURE, CONGESTIVE; HUMANS; HYPERTENSION; MYOCARDIAL INFARCTION; RISK;

EID: 33645741614     PISSN: 14440903     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/j.1445-5994.2006.01056.x     Document Type: Review

References (91)

1. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 1971; 231: 232-5.
2. DeWitt DL, Smith WL. Primary structure of prostaglandin G/H synthase from sheep vesicular gland determined from the complementary DNA sequence. Proc Natl Acad Sci USA 1988; 85: 1412-16.
3. Kujubu DA, Fletcher BS, Varnum BC, Lim RW, Herschman HR. TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue. J Biol Chem 1991; 266: 12 866-72.
4. Chandrasekharan NV, Dai H, Roos KL, Evanson NK, Tomsik J, Elton TS et al. COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc Natl Acad Sci USA 2002; 99: 13 926-31.
5. Vane JR, Bakhle YS, Botting RM. Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol 1998; 38: 97-120.
6. Garcia Rodriguez LA. The effect of NSAIDs on the risk of coronary heart disease: fusion of clinical pharmacology and pharmacoepidemiologic data. Clin Exp Rheumatol 2001; 19(6 Suppl. 25): S41-4.
7. Collaborative overview of randomised trials of antiplatelet therapy - I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration. BMJ 1994; 308: 81-106.
8. Cryer B, Feldman M. Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs. Am J Med 1998; 104: 413-21.
9. Mitchell JA, Akarasereenont P, Thiemermann C, Flower RJ, Vane JR. Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci USA 1993; 90: 11 693-7.
10. Catella-Lawson F, Reilly MP, Kapoor SC, Cucchiara AJ, DeMarco S, Tournier B et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 2001; 345: 1809-17.
11. Reilly IA, FitzGerald GA. Inhibition of thromboxane formation in vivo and ex vivo: implications for therapy with platelet inhibitory drugs. Blood 1987; 69: 180-86.
12. Warner TD, Giuliano F, Vojnovic I, Bukasa A, Mitchell JA, Vane JR. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci USA 1999; 96: 7563-8.
13. Warner TD, Mitchell JA. Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic. FASEB J 2004; 18: 790-804.
14. Capone ML, Sciulli MG, Tacconelli S, Grana M, Ricciotti E, Renda G et al. Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects. J Am Coll Cardiol 2005; 45: 1295-301.
15. MacDonald TM, Wei L. Effect of ibuprofen on cardioprotective effect of aspirin. Lancet 2003; 361: 573-4.
16. Kurth T, Glynn RJ, Walker AM, Chan KA, Buring JE, Hennekens CH et al. Inhibition of clinical benefits of aspirin on first myocardial infarction by nonsteroidal antiinflammatory drugs. Circulation 2003; 108: 1191-5.
17. Schonbeck U, Sukhova GK, Graber P, Coulter S, Libby P. Augmented expression of cyclooxygenase-2 in human atherosclerotic lesions. Am J Pathol 1999; 155: 1281-91.
18. Baker CS, Hall RJ, Evans TJ, Pomerance A, Maclouf J, Creminon C et al. Cyclooxygenase-2 is widely expressed in atherosclerotic lesions affecting native and transplanted human coronary arteries and colocalizes with inducible nitric oxide synthase and nitrotyrosine particularly in macrophages. Arterioscler Thromb Vasc Biol 1999; 19: 646-55.
19. Cipollone F, Toniato E, Martinotti S, Fazia M, Iezzi A, Cuccurullo C et al. A polymorphism in the cyclooxygenase 2 gene as an inherited protective factor against myocardial infarction and stroke. JAMA 2004; 291: 2221-8.
20. Cipollone F, Prontera C, Pini B, Marini M, Fazia M, De Cesare D et al. Overexpression of functionally coupled cyclooxygenase-2 and prostaglandin E synthase in symptomatic atherosclerotic plaques as a basis of prostaglandin E(2)-dependent plaque instability. Circulation 2001; 104: 921-7.
21. Cipollone F, Fazia M, Iezzi A, Pini B, Cuccurullo C, Zucchelli M et al. Blockade of the angiotensin II type 1 receptor stabilizes atherosclerotic plaques in humans by inhibiting prostaglandin E2-dependent matrix metalloproteinase activity. Circulation 2004; 109: 1482-8.
22. Young W, Mahboubi K, Haider A, Li I, Ferreri NR. Cyclooxygenase-2 is required for tumor necrosis factor-alpha- and angiotensin II-mediated proliferation of vascular smooth muscle cells. Circ Res 2000; 86: 906-14.
23. Haider A, Lee I, Grabarek J, Darzynkiewicz Z, Ferreri NR. Dual functionality of cyclooxygenase-2 as a regulator of tumor necrosis factor-mediated G1 shortening and nitric oxide-mediated inhibition of vascular smooth muscle cell proliferation. Circulation 2003; 108: 1015-21.
24. Yang HM, Kim HS, Park KW, You HJ, Jeon SI, Youn SW et al. Celecoxib, a cyclooxygenase-2 inhibitor, reduces neointimal hyperplasia through inhibition of Akt signaling. Circulation 2004; 110: 301-8.
25. Burleigh ME, Babaev VR, Oates JA, Harris RC, Gautam S, Riendeau D et al. Cyclooxygenase-2 promotes early atherosclerotic lesion formation in LDL receptor-deficient mice. Circulation 2002; 105: 1816-23.
26. Belton O, Byrne D, Kearney D, Leahy A, Fitzgerald DJ. Cyclooxygenase-1 and -2-dependent prostacyclin formation in patients with atherosclerosis. Circulation 2000; 102: 840-45.
27. FitzGerald GA, Pedersen AK, Patrono C. Analysis of prostacyclin and thromboxane biosynthesis in cardiovascular disease. Circulation 1983; 67: 1174-7.
28. Maier JA, Barenghi L, Bradamante S, Pagani F. Modulators of oxidized LDL-induced hyperadhesiveness in human endothelial cells. Biochem Biophys Res Commun 1994; 204: 673-7.
29. Pontsler AV, St Hilaire A, Marathe GK, Zimmerman GA, McIntyre TM. Cyclooxygenase-2 is induced in monocytes by peroxisome proliferator activated receptor gamma and oxidized alkyl phospholipids from oxidized low density lipoprotein. J Biol Chem 2002; 277: 13 029-36.
30. Barrios-Rodiles M, Tiraloche G, Chadee K. Lipopolysaccharide modulates cyclooxygenase-2 transcriptionally and posttranscriptionally in human macrophages independently from endogenous IL-1 beta and TNF-alpha. J Immunol 1999; 163: 963-9.
31. Niiro H, Otsuka T, Ogami E, Yamaoka K, Nagano S, Akahoshi M et al. MAP kinase pathways as a route for regulatory mechanisms of IL-10 and IL-4 which inhibit COX-2 expression in human monocytes. Biochem Biophys Res Commun 1998; 250: 200-205.
32. Weber AA, Zimmermann KC, Meyer-Kirchrath J, Schror K. Cyclooxygenase-2 in human platelets as a possible factor in aspirin resistance. Lancet 1999; 353: 900.
33. Cheng Y, Austin SC, Rocca B, Koller BH, Coffman TM, Grosser T et al. Role of prostacyclin in the cardiovascular response to thromboxane A2. Science 2002; 296: 539-41.
34. Reilly M, Fitzgerald GA. Cellular activation by thromboxane A2 and other eicosanoids. Eur Heart J 1993; 14 Suppl. K: 88-93.
35. Loscalzo J. Nitric oxide and vascular disease. N Engl J Med 1995; 333: 251-3.
36. Suwaidi JA, Hamasaki S, Higano ST, Nishimura RA, Holmes DR Jr, Lerman A. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation 2000; 101: 948-54.
37. Schachinger V, Britten MB, Zeiher AM. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 2000; 101: 1899-906.
38. Fichtlscherer S, Rosenberger G, Walter DH, Breuer S, Dimmeler S, Zeiher AM. Elevated C-reactive protein levels and impaired endothelial vasoreactivity in patients with coronary artery disease. Circulation 2000; 102: 1000-1006.
39. Hingorani AD, Cross J, Kharbanda RK, Mullen MJ, Bhagat K, Taylor M et al. Acute systemic inflammation impairs endothelium-dependent dilatation in humans. Circulation 2000; 102: 994-9.
40. Fichtlscherer S, Zeiher AM. Endothelial dysfunction in acute coronary syndromes: association with elevated C-reactive protein levels. Ann Med 2000; 32: 515-18.
41. Verma S,Wang CH, Li SH, Dumont AS, Fedak PW, Badiwala MV et al. A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation 2002; 106: 913-19.
42. Venugopal SK, Devaraj S, Yuhanna I, Shaul P, Jialal I. Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells. Circulation 2002; 106: 1439-41.
43. Verma S, Li SH, Badiwala MV, Weisel RD, Fedak PW, Li RK et al. Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein. Circulation 2002; 105: 1890-96.
44. Pasceri V, Willerson JT, Yeh ET. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 2000; 102: 2165-8.
45. Han KH, Hong KH, Park JH, Ko J, Kang DH, Choi KJ et al. C-reactive protein promotes monocyte chemoattractant protein-1 - mediated chemotaxis through upregulating CC chemokine receptor 2 expression in human monocytes. Circulation 2004; 109: 2566-71.
46. Hurlimann D, Forster A, Noll G, Enseleit F, Chenevard R, Distler O et al. Anti-tumor necrosis factor-alpha treatment improves endothelial function in patients with rheumatoid arthritis. Circulation 2002; 106: 2184-7.
47. Verma S, Raj SR, Shewchuk L, Mather KJ, Anderson TJ. Cyclooxygenase-2 blockade does not impair endothelial vasodilator function in healthy volunteers: randomized evaluation of rofecoxib versus naproxen on endothelium-dependent vasodilatation. Circulation 2001; 104: 2879-82.
48. Chenevard R, Hurlimann D, Bechir M, Enseleit F, Spieker L, Hermann M et al. Selective COX-2 inhibition improves endothelial function in coronary artery disease. Circulation 2003; 107: 405-9.
49. Ridker PM, Buring JE, Shih J, Matias M, Hennekens CH. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 1998; 98: 731-3.
50. Yasojima K, Schwab C, McGeer EG, McGeer PL. Generation of C-reactive protein and complement components in atherosclerotic plaques. Am J Pathol 2001; 158: 1039-51.
51. Libby P. Molecular bases of the acute coronary syndromes. Circulation 1995; 91: 2844-50.
52. Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res 2000; 87: 840-44.
53. Widlansky ME, Price DT, Gokce N, Eberhardt RT, Duffy SJ, Holbrook M et al. Short- and long-term COX-2 inhibition reverses endothelial dysfunction in patients with hypertension. Hypertension 2003; 42: 310-15.
54. Title LM, Giddens K, McInerney MM, McQueen MJ, Nassar BA. Effect of cyclooxygenase-2 inhibition with rofecoxib on endothelial dysfunction and inflammatory markers in patients with coronary artery disease. J Am Coll Cardiol 2003; 42: 1747-53.
55. Monakier D, Mates M, Klutstein MW, Balkin JA, Rudensky B, Meerkin D et al. Rofecoxib, a COX-2 inhibitor, lowers C-reactive protein and interleukin-6 levels in patients with acute coronary syndromes. Chest 2004; 125: 1610-15.
56. Hermann M, Camici G, Fratton A, Hurlimann D, Tanner FC, Hellermann JP et al. Differential effects of selective cyclooxygenase-2 inhibitors on endothelial function in salt-induced hypertension. Circulation 2003; 108: 2308-11.
57. Somers MJ, Mavromatis K, Galis ZS, Harrison DG. Vascular superoxide production and vasomotor function in hypertension induced by deoxycorticosterone acetate-salt. Circulation 2000; 101: 1722-8.
58. Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005; 352: 1092-102.
59. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000; 343: 1520-28, 2 p following 1528.
60. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 2001; 286: 954-9.
61. Curfman GD, Morrissey S, Drazen JM. Expression of concern: Bombardier et al., "Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis." N Engl JMed 2000; 343: 1520-28.
62. N Engl J Med 2005; 353: 2813-14.
63. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000; 284: 1247-55.
64. Solomon SD, McMurray JJ, Pfeffer MA,Wittes J, Fowler R, Finn P et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005; 352: 1071-80.
65. National Institutes of Health (NIH). Use of non-steroidal anti-inflammatory drugs suspended in large Alzheimer's disease prevention trial. NIH News; 2004. Available from: URL: http://www.nih.gov/news/pr/dec2004/od-20. htm
66. Baron JA, Cole BF, Sandler RS, Haile RW, Ahnen D, Bresalier R et al. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 2003; 348: 891-9.
67. Taylor DW, Barnett HJ, Haynes RB, Ferguson GG, Sackett DL, Thorpe KE et al. Low-dose and high-dose acetylsalicylic acid for patients undergoing carotid endarterectomy: a randomised controlled trial. ASA and Carotid Endarterectomy (ACE) Trial Collaborators. Lancet 1999; 353: 2179-84.
68. Nussmeier NA, Whelton AA, Brown MT, Langford RM, Hoeft A, Parlow JL et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 2005; 352: 1081-91.
69. Furberg CD, Psaty BM, FitzGerald GA. Parecoxib, valdecoxib, and cardiovascular risk. Circulation 2005; 111: 249.
70. Whelton A, Nussmeier NA, Martineau RJ et al. Safety of parecoxib and valdecoxib in the treatment of postoperative pain following coronary artery bypass graft surgery or major general surgery. In: American College of Cardiology Annual Scientific Session, 2005; Orlando, Florida; 2005.
71. Mamdani M, Rochon P, Juurlink DN, Anderson GM, Kopp A, Naglie G et al. Effect of selective cyclooxygenase 2 inhibitors and naproxen on short-term risk of acute myocardial infarction in the elderly. Arch Intern Med 2003; 163: 481-6.
72. Reicin AS, Shapiro D, Sperling RS, Barr E, Yu Q. Comparison of cardiovascular thrombotic events in patients with osteoarthritis treated with rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs (ibuprofen, diclofenac, and nabumetone). Am J Cardiol 2002; 89: 204-9.
73. Ray WA, Stein CM, Daugherty JR, Hall K, Arbogast PG, Griffin MR. COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet 2002; 360: 1071-3.
74. Graham DJ, Campen D, Hui R, Spence M, Cheetham C, Levy G et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet 2005; 365: 475-81.
75. Singh G, Mithal A, Triadafilopoulos G. Both selective COX-2 inhibitors and non-selective NSAIDs increase the risk of acute myocardial infarction in patients with arthritis: Selectivity is with the patient, not the drugclass. In: EULAR; Vienna; 2005.
76. Solomon DH, Schneeweiss S, Glynn RJ, Kiyota Y, Levin R, Mogun H et al. Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. Circulation 2004; 109: 2068-73.
77. Johnsen SP, Larsson H, Tarone RE, McLaughlin JK, Norgard B, Friis S et al. Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: a population-based case-control study. Arch Intern Med 2005; 165: 978-84.
78. Sowers JR, White WB, Pitt B, Whelton A, Simon LS, Winer N et al. The effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus. Arch Intern Med 2005; 165: 161-8.
79. Strand V, Hochberg MC. The risk of cardiovascular thrombotic events with selective cyclooxygenase-2 inhibitors. Arthritis Rheum 2002; 47: 349-55.
80. Solomon DH, Schneeweiss S, Levin R, Avorn J. Relationship between COX-2 specific inhibitors and hypertension. Hypertension 2004; 44: 140-45.
81. Mamdani M, Juurlink DN, Lee DS, Rochon PA, Kopp A, Naglie G et al. Cyclo-oxygenase-2 inhibitors versusn on-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study. Lancet 2004; 363: 1751-6.
82. Hudson M, Richard H, Pilote L. Differences in outcomes of patients with congestive heart failure prescribed celecoxib, rofecoxib, or non-steroidal anti-inflammatory drugs: population based study. BMJ 2005; 330: 1370.
83. Pitt B, Pepine C, Willerson JT. Cyclooxygenase-2 inhibition and cardiovascular events. Circulation 2002; 106: 167-9.
84. Walter MF, Jacob RF, Day CA, Dahlborg R, Weng Y, Mason RP. Sulfone COX-2 inhibitors increase susceptibility of human LDL and plasma to oxidative modification: comparison to sulfonamide COX-2 inhibitorsa nd NSAIDs. Atherosclerosis 2004; 177: 235-43.
85. Steffel J, Hermann M, Greutert H, Gay S, Luscher TF, Ruschitzka F et al. Celecoxib decreases endothelial tissue factor expression through inhibition of c-Jun terminal NH2 kinase phosphorylation. Circulation 2005; 111: 1685-9.
86. Matsumoto AK, Melian A, Mandel DR, McIlwain HH, Borenstein D, Zhao PL et al. A randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis. J Rheumatol 2002; 29: 1623-30.
87. Curtis SP, Ng J, Yu Q, Shingo S, Bergman G, McCormick CL et al. Renal effects of etoricoxib and comparator nonsteroidal anti-inflammatory drugs in controlled clinical trials. Clin Ther 2004; 26: 70-83.
88. Farkouh ME, Kirshner H, Harrington RA, Ruland S, Verheugt FW, Schnitzer TJ et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial. Lancet 2004; 364: 675-84.
89. White WB, Faich G, Whelton A, Maurath C, Ridge NJ, Verburg KM et al. Comparison of thromboembolic events in patients treated with celecoxib, a cyclooxygenase-2 specific inhibitor, versus ibuprofen or diclofenac. Am J Cardiol 2002; 89: 425-30.
90. Kimmel SE, Berlin JA, Reilly M, Jaskowiak J, Kishel L, Chittams J et al. Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction. Ann Intern Med 2005; 142: 157-64.
91. Hippisley-Cox J, Coupland C. Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: